CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01330953
NCT01330953Phase 1Completed
CompareCT.gov

A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Apr 7, 2011·Updated Jul 30, 2018

In Brief

A Phase 1 clinical trial evaluating Placebo and LY2928057 for Healthy Volunteers. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purposes of this study are to evaluate the following in healthy participants: 1) LY2928057 safety, including any side effects possibly associated with LY2928057; 2) how the body processes LY2928057; 3) effect of LY2928057 on blood iron levels; and 4) immune system reactions to LY2928057.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 7, 2011
Enrollment StartMar 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.2 years ago

Interventions

Placebodrug

Single intravenous placebo dose.

LY2928057drug

Single intravenous dose.